Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models:  Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites

View Author Information
Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15217, Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486, Department of Medicinal Chemistry, University of Washington, Seattle, Washington 98195, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, and Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia 26506
Cite this: Biochemistry 1998, 37, 12, 4137–4147
Publication Date (Web):March 3, 1998
Copyright © 1998 American Chemical Society

    Article Views





    Other access options


    Some cytochrome P450 catalyzed reactions show atypical kinetics, and these kinetic processes can be grouped into five categories:  activation, autoactivation, partial inhibition, substrate inhibition, and biphasic saturation curves. A two-site model in which the enzyme can bind two substrate molecules simultaneously is presented which can be used to describe all of these observed kinetic properties. Sigmoidal kinetic characteristics were observed for carbamazepine metabolism by CYP3A4 and naphthalene metabolism by CYPs 2B6, 2C8, 2C9, and 3A5 as well as dapsone metabolism by CYP2C9. Naphthalene metabolism by CYP3A4 and naproxen metabolism by CYP2C9 demonstrated nonhyperbolic enzyme kinetics suggestive of a low Km, low Vmax component for the first substrate molecule and a high Km, high Vmax component for the second substrate molecule. 7,8-Benzoflavone activation of phenanthrene metabolism by CYP3A4 and dapsone activation of flurbiprofen and naproxen metabolism by CYP2C9 were also observed. Furthermore, partial inhibition of 7,8-benzoflavone metabolism by phenanthrene was observed. These results demonstrate that various P450 isoforms may exhibit atypical enzyme kinetics depending on the substrate(s) employed and that these results may be explained by a model which includes simultaneous binding of two substrate molecules in the active site.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     Supported by NSF Grant OSR-9450578 and NIH Grants NO1-DK-6-2274 and GM32165.


     To whom correspondence should be addressed at the Center for Clinical Pharmacology, 623 Scaife Hall, University of Pittsburgh Medical Center, Pittsburgh, PA 15213.

     University of Pittsburgh.


     Merck Research Laboratories.

     University of Washington.

     National Cancer Institute.


     West Virginia University.

    Cited By

    This article is cited by 411 publications.

    1. Yanjun Feng, Changda Gong, Jieyu Zhu, Guixia Liu, Yun Tang, Weihua Li. Unraveling the Ligand-Binding Sites of CYP3A4 by Molecular Dynamics Simulations with Solvent Probes. Journal of Chemical Information and Modeling 2024, 64 (8) , 3451-3464.
    2. Rong-Jing He, Zhen-Hao Tian, Jian Huang, Meng-Ru Sun, Feng Wei, Chun-Yu Li, Hai-Rong Zeng, Feng Zhang, Xiao-Qing Guan, Yan Feng, Xiang-Ming Meng, Hui Yang, Guang-Bo Ge. Rationally Engineered CYP3A4 Fluorogenic Substrates for Functional Imaging Analysis and Drug–Drug Interaction Studies. Journal of Medicinal Chemistry 2023, 66 (10) , 6743-6755.
    3. Bethany D. Latham, D. Spencer Oskin, Rachel D. Crouch, Matthew J. Vergne, Klarissa D. Jackson. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chemical Research in Toxicology 2022, 35 (9) , 1467-1481.
    4. Ilia G. Denisov, Yelena V. Grinkova, Tyler Camp, Mark A. McLean, Stephen G. Sligar. Midazolam as a Probe for Drug–Drug Interactions Mediated by CYP3A4: Homotropic Allosteric Mechanism of Site-Specific Hydroxylation. Biochemistry 2021, 60 (21) , 1670-1681.
    5. Julie Ducharme, Vanja Polic, Christopher J. Thibodeaux, Karine Auclair. Combining Small-Molecule Bioconjugation and Hydrogen–Deuterium Exchange Mass Spectrometry (HDX-MS) to Expose Allostery: the Case of Human Cytochrome P450 3A4. ACS Chemical Biology 2021, 16 (5) , 882-890.
    6. Kang Xiao, Jie Gao, Shi-Jia Weng, Yan Fang, Na Gao, Qiang Wen, Han Jin, Hai-Ling Qiao. CYP3A4/5 Activity Probed with Testosterone and Midazolam: Correlation between Two Substrates at the Microsomal and Enzyme Levels. Molecular Pharmaceutics 2019, 16 (1) , 382-392.
    7. Jaydeep Yadav, Ken Korzekwa, Swati Nagar. Improved Predictions of Drug–Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. Molecular Pharmaceutics 2018, 15 (5) , 1979-1995.
    8. Ilia G. Denisov, Javier L. Baylon, Yelena V. Grinkova, Emad Tajkhorshid, and Stephen G. Sligar . Drug–Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4. Biochemistry 2018, 57 (5) , 805-816.
    9. Keiko Maekawa, Motoyasu Adachi, Yumiko Matsuzawa, Qinghai Zhang, Ryota Kuroki, Yoshiro Saito, and Manish B. Shah . Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. Biochemistry 2017, 56 (41) , 5476-5480.
    10. Matthew D. DeMars, II, Fang Sheng, Sung Ryeol Park, Andrew N. Lowell, Larissa M. Podust, and David H. Sherman . Biochemical and Structural Characterization of MycCI, a Versatile P450 Biocatalyst from the Mycinamicin Biosynthetic Pathway. ACS Chemical Biology 2016, 11 (9) , 2642-2654.
    11. Carlo Barnaba, Jaydeep Yadav, Swati Nagar, Ken Korzekwa, and Jeffrey P. Jones . Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations. Molecular Pharmaceutics 2016, 13 (8) , 2833-2843.
    12. Carlo Barnaba, Sara C. Humphreys, Adam O. Barden, Jeffrey P. Jones, and James A. Brozik . Substrate Dependent Native Luminescence from Cytochromes P450 3A4, 2C9, and P450cam. The Journal of Physical Chemistry B 2016, 120 (12) , 3038-3047.
    13. Irina F. Sevrioukova and Thomas L. Poulos . Anion-Dependent Stimulation of CYP3A4 Monooxygenase. Biochemistry 2015, 54 (26) , 4083-4096.
    14. Christian S. Müller, Tim Knehans, Dmitri R. Davydov, Patricia L. Bounds, Ursula von Mandach, James R. Halpert, Amedeo Caflisch, and Willem H. Koppenol . Concurrent Cooperativity and Substrate Inhibition in the Epoxidation of Carbamazepine by Cytochrome P450 3A4 Active Site Mutants Inspired by Molecular Dynamics Simulations. Biochemistry 2015, 54 (3) , 711-721.
    15. W. Kurtis Childers and John P. Harrelson . Allosteric Modulation of Substrate Motion in Cytochrome P450 3A4-Mediated Xylene Oxidation. Biochemistry 2014, 53 (6) , 1018-1028.
    16. Jue Li, Dong-Qing Wei, Jing-Fang Wang, and Yi-Xue Li . A Negative Cooperativity Mechanism of Human CYP2E1 Inferred from Molecular Dynamics Simulations and Free Energy Calculations. Journal of Chemical Information and Modeling 2011, 51 (12) , 3217-3225.
    17. Arthur G. Roberts, Jing Yang, James R. Halpert, Sidney D. Nelson, Kenneth T. Thummel, and William M. Atkins . The Structural Basis for Homotropic and Heterotropic Cooperativity of Midazolam Metabolism by Human Cytochrome P450 3A4. Biochemistry 2011, 50 (50) , 10804-10818.
    18. Caleb M. Woods, Cristina Fernandez, Kent L. Kunze, and William M. Atkins . Allosteric Activation of Cytochrome P450 3A4 by α-Naphthoflavone: Branch Point Regulation Revealed by Isotope Dilution Analysis. Biochemistry 2011, 50 (46) , 10041-10051.
    19. Alfonso T. García-Sosa, Sulev Sild, Kalev Takkis, and Uko Maran . Combined Approach Using Ligand Efficiency, Cross-Docking, and Antitarget Hits for Wild-Type and Drug-Resistant Y181C HIV-1 Reverse Transcriptase. Journal of Chemical Information and Modeling 2011, 51 (10) , 2595-2611.
    20. William M. Atkins and Hong Qian . Stochastic Ensembles, Conformationally Adaptive Teamwork, and Enzymatic Detoxification. Biochemistry 2011, 50 (19) , 3866-3872.
    21. Arthur G. Roberts, Matthew J. Cheesman, Andrew Primak, Michael K. Bowman, William M. Atkins, and Allan E. Rettie . Intramolecular Heme Ligation of the Cytochrome P450 2C9 R108H Mutant Demonstrates Pronounced Conformational Flexibility of the B−C Loop Region: Implications for Substrate Binding. Biochemistry 2010, 49 (40) , 8700-8708.
    22. Josh T. Pearson, Sophia Siu, David P. Meininger, Larry C. Wienkers and Dan A. Rock . In Vitro Modulation of Cytochrome P450 Reductase Supported Indoleamine 2,3-Dioxygenase Activity by Allosteric Effectors Cytochrome b5 and Methylene Blue. Biochemistry 2010, 49 (12) , 2647-2656.
    23. Stefan Balaz. Modeling Kinetics of Subcellular Disposition of Chemicals. Chemical Reviews 2009, 109 (5) , 1793-1899.
    24. Carrie M. Mosher, Matthew A. Hummel, Timothy S. Tracy and Allan E. Rettie . Functional Analysis of Phenylalanine Residues in the Active Site of Cytochrome P450 2C9. Biochemistry 2008, 47 (45) , 11725-11734.
    25. Dmitri R. Davydov, Nadezhda Y. Davydova and James R. Halpert. Allosteric Transitions in Cytochrome P450eryF Explored with Pressure-Perturbation Spectroscopy, Lifetime FRET, and a Novel Fluorescent Substrate, Fluorol-7GA. Biochemistry 2008, 47 (43) , 11348-11359.
    26. John P. Harrelson, William M. Atkins and Sidney D. Nelson. Multiple-Ligand Binding in CYP2A6: Probing Mechanisms of Cytochrome P450 Cooperativity by Assessing Substrate Dynamics. Biochemistry 2008, 47 (9) , 2978-2988.
    27. Matthew G. McDonald and Allan E. Rettie. Sequential Metabolism and Bioactivation of the Hepatotoxin Benzbromarone: Formation of Glutathione Adducts From a Catechol Intermediate. Chemical Research in Toxicology 2007, 20 (12) , 1833-1842.
    28. Slobodan P. Rendic, F. Peter Guengerich. Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes. Archives of Toxicology 2024, 98 (6) , 1581-1628.
    29. Shuhui Liu, Tao Jing, Ran Jia, Ji-Long Zhang, Fu-Quan Bai. MD investigation on the differences in the dynamic interactions between the specific ligand azamulin and two CYP3A isoforms, 3A4 and 3A5. Journal of Biomolecular Structure and Dynamics 2024, , 1-10.
    30. Haiying Mo, Xin Chen, Manwen Tang, Ying Qu, Zhihao Li, Wang Liu, Chunlin Yang, Yijian Chen, Jingxian Sun, Haiying Yang, Gang Du. Expression of a thermostable glucose-stimulated β-glucosidase from a hot-spring metagenome and its promising application to produce gardenia blue. Bioorganic Chemistry 2024, 143 , 107036.
    31. Angela Hayward, Benjamin J. Hunt, Julian Haas, Ellie Bushnell‐Crowther, Bartlomiej J. Troczka, Adam Pym, Katherine Beadle, Jeremy Field, David R. Nelson, Ralf Nauen, Chris Bass. A cytochrome P450 insecticide detoxification mechanism is not conserved across the Megachilidae family of bees. Evolutionary Applications 2023, 13
    32. Pramod C. Nair, Kushari Burns, Nuy Chau, Ross A. McKinnon, John O. Miners. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation. Journal of Biological Chemistry 2023, 299 (12) , 105368.
    33. J. Patrick Connick, James R. Reed, George F. Cawley, Aratrika Saha, Wayne L. Backes. Functional characterization of CYP1 enzymes: Complex formation, membrane localization and function. Journal of Inorganic Biochemistry 2023, 247 , 112325.
    34. Tatiana A. Filippova, Rami A. Masamrekh, Victoria V. Shumyantseva, Yulia Yu. Khudoklinova, Alexey V. Kuzikov. Voltammetric Analysis of (S)-O-Desmethylnaproxen for Determination of CYP2C9 Demethylase Activity. BioNanoScience 2023, 13 (3) , 1278-1288.
    35. Cyrus Khojasteh, Jasleen K. Sodhi, Jason Halladay, Donglu Zhang. The past decade of Genentech experience in elucidation of novel reaction mechanisms in drug metabolism. Medicinal Chemistry Research 2023, 32 (9) , 2016-2033.
    36. Marzieh Dehghan Shasaltaneh, Elmira Naghdi, Zahra Moosavi-Nejad. Mechanistic studies on substrate inhibition and substrate activation of ribonuclease A: experimental and in silico investigation. Journal of Biomolecular Structure and Dynamics 2023, 28 , 1-17.
    37. Suzana Mustafa, Mahiran Mustafa, Wan Nazirah Wan Yusuf. Methadone Reduced Nevirapine Pharmacokinetic Parameters in People Living With HIV in Malaysia. Malaysian Journal of Medicine and Health Sciences 2023, 19 (3) , 247-253.
    38. Hening Lin. Substrate-selective small-molecule modulators of enzymes: Mechanisms and opportunities. Current Opinion in Chemical Biology 2023, 72 , 102231.
    39. Lina Shan, Xianbao Shi, Tingting Hu, Jiayin Hu, Zhe Guo, Yonggui Song, Dan Su, Xiaoyong Zhang. In vitro differences in toddalolactone metabolism in various species and its effect on cytochrome P450 expression. Pharmaceutical Biology 2022, 60 (1) , 1591-1605.
    40. Alexey V. Kuzikov, Tatiana A. Filippova, Rami A. Masamrekh, Victoria V. Shumyantseva. Biotransformation of phenytoin in the electrochemically-driven CYP2C19 system. Biophysical Chemistry 2022, 291 , 106894.
    41. Ziteng Wang, Eric Chun Yong Chan. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib. Drug Metabolism and Disposition 2022, 50 (10) , 1332-1341.
    42. Julian Haas, Angela Hayward, Benjamin Buer, Frank Maiwald, Birgit Nebelsiek, Johannes Glaubitz, Chris Bass, Ralf Nauen. Phylogenomic and functional characterization of an evolutionary conserved cytochrome P450-based insecticide detoxification mechanism in bees. Proceedings of the National Academy of Sciences 2022, 119 (26)
    43. Ilia G. Denisov, Yelena V. Grinkova, Mark A. McLean, Tyler Camp, Stephen G. Sligar. Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4. Biomolecules 2022, 12 (6) , 853.
    44. Mei-Hui Hsu, Eric F. Johnson. Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5. Journal of Biological Chemistry 2022, 298 (5) , 101909.
    45. Komal Agrawal, Pradeep Verma. Enzyme Kinetics: A Plethora of Information. 2022, 195-211.
    46. Alan Talevi, Carolina L. Bellera. Drug Metabolism. 2022, 362-368.
    47. Zeyuan Wang, Erickson M. Paragas, Swati Nagar, Ken Korzekwa. Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 1. Theoretical Considerations. Drug Metabolism and Disposition 2021, 49 (12) , 1090-1099.
    48. Erickson M. Paragas, Zeyuan Wang, Ken Korzekwa, Swati Nagar. Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 2. Modeling of Experimental Data. Drug Metabolism and Disposition 2021, 49 (12) , 1100-1108.
    49. William R. Arnold, Lauren N. Carnevale, Zili Xie, Javier L. Baylon, Emad Tajkhorshid, Hongzhen Hu, Aditi Das. Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. Nature Communications 2021, 12 (1)
    50. Lloyd Wei Tat Tang, Ravi Kumar Verma, Ren Ping Yong, Xin Li, Lili Wang, Qingsong Lin, Hao Fan, Eric Chun Yong Chan. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5. Molecular Pharmacology 2021, 100 (3) , 224-236.
    51. Eric Gonzalez, Sankalp Jain, Pranav Shah, Nao Torimoto-Katori, Alexey Zakharov, Ðắc-Trung Nguyễn, Srilatha Sakamuru, Ruili Huang, Menghang Xia, R. Scott Obach, Cornelis E. C. A. Hop, Anton Simeonov, Xin Xu. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition. Drug Metabolism and Disposition 2021, 49 (9) , 822-832.
    52. Jacqueline Wen Hui Leow, Ravi Kumar Verma, Amos Boon Hao Lim, Hao Fan, Eric Chun Yong Chan. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors. European Journal of Pharmaceutical Sciences 2021, 164 , 105889.
    53. Saneesh Kumar, Patrick J. Bouic, Bernd Rosenkranz. Investigation of CYP2B6, 3A4 and β-esterase interactions of Withania somnifera (L.) dunal in human liver microsomes and HepG2 cells. Journal of Ethnopharmacology 2021, 270 , 113766.
    54. Julian Haas, Ralf Nauen. Pesticide risk assessment at the molecular level using honey bee cytochrome P450 enzymes: A complementary approach. Environment International 2021, 147 , 106372.
    55. Slobodan P. Rendic, F. Peter Guengerich. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Archives of Toxicology 2021, 95 (2) , 395-472.
    56. P. I. Koroleva, A. V. Kuzikov, R. A. Masamrekh, D. A. Filimonov, A. V. Dmitriev, M. G. Zaviyalova, S. M. Rikova, E. V. Shich, A. A. Makhova, T. V. Bulko, A. A. Gilep, V. V. Shumyantseva. Modeling of Drug-Drug Interactions between Omeprazole and Erythromycin in the Cytochrome P450-Dependent System In vitro. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry 2021, 15 (1) , 62-70.
    57. Alan Talevi, Carolina L. Bellera. Drug Metabolism. 2021, 1-7.
    58. Nagendra Sai Kumar Achanta, Kuldeep Rajpoot, Rakesh Kumar Tekade. Drug metabolic kinetics. 2021, 335-353.
    59. David M. Stresser, Arian Emami-Riedmaier. Case Study 3: Criticality of High-Quality Curve Fitting—“Getting a Km,app” Isn’t as Simple as It May Seem. 2021, 653-664.
    60. Michael Mohutsky, Stephen D. Hall. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions. 2021, 51-88.
    61. Eleanore Seibert, Timothy S. Tracy. Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis–Type (Atypical) Enzyme Kinetics. 2021, 3-27.
    62. Erickson M. Paragas, Kanika Choughule, Jeffrey P. Jones, John T. Barr. Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase. 2021, 257-284.
    63. Ken Korzekwa. Enzyme Kinetics of Oxidative Metabolism—Cytochromes P450. 2021, 237-256.
    64. D. Fernando Estrada, Amit Kumar, Christopher S. Campomizzi, Natalie Jay. Crystal Structures of Drug-Metabolizing CYPs. 2021, 171-192.
    65. Jaydeep Yadav, Ken Korzekwa, Swati Nagar. Numerical Methods for Modeling Enzyme Kinetics. 2021, 147-168.
    66. Jasleen K. Sodhi, Jason S. Halladay. Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). 2021, 765-779.
    67. Heather K. Knych, Carrie J. Finno, Russell Baden, Rick M. Arthur, Daniel S. McKemie. Identification and characterization of the enzymes responsible for the metabolism of the non‐steroidal anti‐inflammatory drugs, flunixin meglumine and phenylbutazone, in horses. Journal of Veterinary Pharmacology and Therapeutics 2021, 44 (1) , 36-46.
    68. Beatriz Carvalho Henriques, Esther H. Yang, Diego Lapetina, Michael S. Carr, Vasyl Yavorskyy, Joshua Hague, Katherine J. Aitchison. How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Frontiers in Genetics 2020, 11
    69. Aditi Das, Austin T. Weigle, William R. Arnold, Justin S. Kim, Lauren N. Carnevale, Hannah C. Huff. CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. Pharmacology & Therapeutics 2020, 215 , 107601.
    70. Michael J. Espiritu, Justin Chen, Jaydeep Yadav, Michael Larkin, Robert D. Pelletier, Jeannine M. Chan, Jeevan B. GC, Senthil Natesan, John P. Harrelson. Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. Drug Metabolism and Disposition 2020, 48 (10) , 1028-1043.
    71. Bharath Srinivasan, Vasudev Kantae, James Robinson. Resurrecting the phoenix: When an assay fails. Medicinal Research Reviews 2020, 40 (5) , 1776-1793.
    72. Josemarco Mendoza-Avila, Kanchan Chauhan, Rafael Vazquez-Duhalt. Enzymatic synthesis of indigo-derivative industrial dyes. Dyes and Pigments 2020, 178 , 108384.
    73. Diego L. Lapetina, Esther H. Yang, Beatriz C. Henriques, Katherine J. Aitchison. Pharmacogenomics and Psychopharmacology. 2020, 151-202.
    74. P.I. Koroleva, A.V. Kuzikov, R.A. Masamrekh, D.A. Filimonov, A.V. Dmitriev, M.G. Zaviyalova, S.M. Rikova, E.V. Shich, A.A. Makhova, T.V. Bulko, A.A. Gilep, V.V. Shumyantseva. Modeling of drug-drug interactions between omeprazole and erythromycin with cytochrome P450 3A4 in vitro assay. Biomeditsinskaya Khimiya 2020, 66 (3) , 241-249.
    75. Jaydeep Yadav, Erickson Paragas, Ken Korzekwa, Swati Nagar. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacology & Therapeutics 2020, 206 , 107449.
    76. Jie Bai, Li Li, Shengyu Zhao, Xiaoqing Fan, Jie Zhang, Minwan Hu, Yonghui Chen, Yanhong Sun, Baolian Wang, Jing Jin, Xiaojian Wang, Dan Zhang, Jinping Hu, Yan Li. Heterotropic activation of flavonoids on cytochrome P450 3A4: A case example of alleviating dronedarone-induced cytotoxicity. Toxicology Letters 2020, 319 , 187-196.
    77. Jan Wahlstrom, Larry Wienkers. In Vitro/In Vivo Correlation for Drug-Drug Interactions. 2020, 847-866.
    78. Huanwen Chen, John Kuhn, Kathleen R Lamborn, Lauren E Abrey, Lisa M DeAngelis, Frank Lieberman, H Ian Robins, Susan M Chang, W K Alfred Yung, Jan Drappatz, Minesh P Mehta, Victor A Levin, Kenneth Aldape, Janet E Dancey, John J Wright, Michael D Prados, Timothy F Cloughesy, Patrick Y Wen, Mark R Gilbert. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances 2020, 2 (1)
    79. Jacqueline Wen Hui Leow, Eric Chun Yong Chan. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition. Biochemical Pharmacology 2019, 169 , 113615.
    80. Junho Jeon, Juliane Hollender. In vitro biotransformation of pharmaceuticals and pesticides by trout liver S9 in the presence and absence of carbamazepine. Ecotoxicology and Environmental Safety 2019, 183 , 109513.
    81. F. Peter Guengerich. Kinetic Modeling of Steady-State Situations in Cytochrome P450 Enzyme Reactions. Drug Metabolism and Disposition 2019, 47 (11) , 1232-1239.
    82. Haixing Li, Jed N. Lampe. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Archives of Biochemistry and Biophysics 2019, 673 , 108078.
    83. Jaydeep Yadav, Ken Korzekwa, Swati Nagar. Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation. Drug Metabolism and Disposition 2019, 47 (7) , 732-742.
    84. Hosam Eldin Dahshan, Mohamed A. Helal, Samia M. Mostafa, Mohamed Saleh Elgawish. Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. Journal of Pharmaceutical and Biomedical Analysis 2019, 168 , 201-208.
    85. Armina Abbasi, Erickson M. Paragas, Carolyn A. Joswig-Jones, John T. Rodgers, Jeffrey P. Jones. Time Course of Aldehyde Oxidase and Why It Is Nonlinear. Drug Metabolism and Disposition 2019, 47 (5) , 473-483.
    86. Giacomo Parisi, Linda Celeste Montemiglio, Alessandro Giuffrè, Alberto Macone, Antonella Scaglione, Gabriele Cerutti, Cécile Exertier, Carmelinda Savino, Beatrice Vallone. Substrate‐induced conformational change in cytochrome P450 OleP. The FASEB Journal 2019, 33 (2) , 1787-1800.
    87. Tomohiko Ichikawa, Hirofumi Tsujino, Takahiro Miki, Masaya Kobayashi, Chiaki Matsubara, Sara Miyata, Taku Yamashita, Kohei Takeshita, Yasushige Yonezawa, Tadayuki Uno. Allosteric activation of cytochrome P450 3A4 by efavirenz facilitates midazolam binding. Xenobiotica 2018, 48 (12) , 1227-1236.
    88. Larry House, Michael J. Seminerio, Snezana Mirkov, Jacqueline Ramirez, Maxwell Skor, Joseph R. Sachleben, Masis Isikbay, Hari Singhal, Geoffrey L. Greene, Donald Vander Griend, Suzanne D. Conzen, Mark J. Ratain. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 2018, 48 (10) , 973-983.
    89. Tashinga E. Bapiro, Andy Sykes, Scott Martin, Michael Davies, James W. T. Yates, Matthias Hoch, Helen E. Rollison, Barry Jones. Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader. Drug Metabolism and Disposition 2018, 46 (9) , 1268-1276.
    90. Ravindranath Reddy Gilibili, Vishwanath Kurawattimath, Bokka Venkata Murali, Yurong Lai, T. Thanga Mariappan, Hong Shen, Sagnik Chatterjee. In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats. Pharmaceutics 2018, 10 (3) , 125.
    91. Sascha K. Manier, Lilian H.J. Richter, Jan Schäper, Hans H. Maurer, Markus R. Meyer. Different in vitro and in vivo tools for elucidating the human metabolism of alpha‐cathinone‐derived drugs of abuse. Drug Testing and Analysis 2018, 10 (7) , 1119-1130.
    92. Helinä Kahma, Anne M. Filppula, Mikko Neuvonen, E. Katriina Tarkiainen, Aleksi Tornio, Mikko T. Holmberg, Matti K. Itkonen, Moshe Finel, Pertti J. Neuvonen, Mikko Niemi, Janne T. Backman. Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions  . Drug Metabolism and Disposition 2018, 46 (2) , 141-150.
    93. Jan Wahlstrom, Larry Wienkers. In Vitro/In Vivo Correlation for Drug-Drug Interactions. 2018, 1-20.
    94. Julie Ducharme, Karine Auclair. Use of bioconjugation with cytochrome P450 enzymes. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2018, 1866 (1) , 32-51.
    95. Hend A.A. Abd El-wahab, Mauro Accietto, Leonardo B. Marino, Kirsty J. McLean, Colin W. Levy, Hamdy M. Abdel-Rahman, Mahmoud A. El-Gendy, Andrew W. Munro, Ahmed S. Aboraia, Claire Simons. Design, synthesis and evaluation against Mycobacterium tuberculosis of azole piperazine derivatives as dicyclotyrosine (cYY) mimics. Bioorganic & Medicinal Chemistry 2018, 26 (1) , 161-176.
    96. Piotr J. Mak, Ilia G. Denisov. Spectroscopic studies of the cytochrome P450 reaction mechanisms. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2018, 1866 (1) , 178-204.
    97. Huifang Xu, Linlin Ning, Wenxia Yang, Bo Fang, Cong Wang, Yun Wang, Jian Xu, Severine Collin, Frederic Laeuffer, Laurent Fourage, Shengying Li. In vitro oxidative decarboxylation of free fatty acids to terminal alkenes by two new P450 peroxygenases. Biotechnology for Biofuels 2017, 10 (1)
    98. Radhakrishnan S. Jisha, Lilly Aswathy, Vijay H. Masand, Jayant M. Gajbhiye, Indira G. Shibi. Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques. In Silico Pharmacology 2017, 5 (1)
    99. Li Di. Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opinion on Drug Discovery 2017, 12 (11) , 1105-1115.
    100. Shuowen Tang, Ang Chen, Xiaojing Zhou, Li Zeng, Mingyao Liu, Xin Wang. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicology Letters 2017, 281 , 74-83.
    Load more citations